Exploratory clinical trial of the new third line Helicobacter pylori eradication therapy using vonoprazan

Exploratory clinical trial of the new third line Helicobacter pylori eradication therapy using vonoprazan - Efficacy of the new third line Helicobacter pylori eradication therapy using vonoprazan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018835

Enrollment

120

Registered

2015-09-01

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter infection with previous eradication failure

Interventions

Vonoprazan 20mg bid Amoxicillin 750mg bid Sitafloxacin 100mg bid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with two eradication failures by clarithromycin and metronidazole based regimen

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Allergy for the study drugs Severe major organ dysfunction Patients who are judged by the investigators to be inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Eradication rate of Helicobacter pylori 8-12 wks after treatment	—

Secondary

Measure	Time frame
Rate of adverse events	—

Countries

Japan

Contacts

Public ContactAtsuo Yamada

The University of Tokyo Department of Gastroenterology

yamada-a@umin.ac.jp+81-3-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026